Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacology > muscle relaxants > Flashcards

muscle relaxants Flashcards

(63 cards)

Start Studying
1
Q

what are central muscle relaxants

A

they cause decreased motor activity or paralysis of voluntary muscles without loss of consciousness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

medical uses of central muscle relaxants

A
  • central myorelaxants can potentiate the effect of anaesthetic drugs and combos
  • they are also used to control certain spasmodic and painful disorders of skeletal muscles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

guaiphenesin effect

A
  • a spinal interneuronal blocking agent, blocks polysynaptic but not monosynaptic relfexes
  • effective against convulsion
  • paralyses limb muscles, whilst resp muscles unaffected
  • consciousness retained
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

guaiphenesin is effective against convulsion caused by which agents

A

strychnine and tetanus but not picrotoxin and leptazol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

guaiphenesin secondary effect

A

expectorant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

guaiphenesin indications

A
  • horse, cattle, sheep - to adjunct anaesthesia

- dogs - strychnine poisoning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

guaiphenesin onset and elimination

A

fats, 2-4 and 60-80min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

guaiphenesin distribution

A

large distribution, crosses the placenta barrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

guaiphenesin metabolism

A

conjugation with glucoronide -> excretion with urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

guaiphenesin side effects

A
  • mild at therapeutic dose slight decrease of blood pressure
  • only large doses cause resp depression
  • haemolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

guaiphenesin dosing

A

due to low potency and conc large volume required

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

baclophen action

A
  • GABAb receptors agonist in the brain and spinal cord
  • hyperpolarisation of neurons due to incr K+ ion conductance
  • inhibits neural funct presynaptically, by reducing Ca ion influx-> reduced release of excitatory NTs in brain and spinal cord
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

baclophen analgesic activity

A

may reduce pain by inhibiting the release of SP in the spinal cord

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

baclophen therapeutic index

A

large

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

baclophen clinical signs of toxicosis

A
  • vomiting
  • ataxia
  • vocalisation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

baclophen indications

A
  • spasm of skeletal muscles or rigidity
  • spinal cord injury and pain caused by injuries
  • extralabel use in dogs to treat urinary retention by reducing urethral resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

baclophen dose

A

1-2mg/kg orally TID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

carisoprodol analgesic abilites

A

especially useful against various types of pain because of its analgesic-sparing effect on opioid analgesics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

carisoprodol effect on convulsions

A

inactive in convulsions caused by strychnine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

carisoprodol avaliability

A

by itself or mixed with aspirin and in one preparation along with codeine and caffeine as well

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

methocarbamol features

A
  • acts on internunical neurons of the spinal cord

- reduces skeletal muscle hyperactivity without alteration in muscle tone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

classes of neuromuscular blocking agents

A
  • depolarising neuromuscular blocking agents

- competitive neuromuscular blocking agents, prototype curare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

whats a nicotinic receptor

A

a transmembrane ion channel receptor, a pentameric asymmetric molecule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

where are the ligand occupation sites on nicotinic receptors

A

alpha units

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
do depolarising agents or non depolarising agents act similiarly to Ach
depolarising
26
uses of neuromuscular blocking agents by IV or systemic administration
- adjuvant in surgical anaesthesia to obtain relaxation of skeletal muscle - balanced anaesthesia, TIVA - to assist in intubation -esp succinylcholine - corneal or retinal surgeries to obtain relaxation of extraocular muscles - therapy of spastic disorders
27
uses of neuromuscular blocking agents by topical administration
mydriasis in birds and reptiles - only non depolarising
28
succinylcholine mechanism
- stimulate opening of nicotinic receptors and produce depolarisation of cell membranes - persists at neuroeffector junction and activates the nicotinic receptor channels cont. - inactivation of voltag egated sodium channels so they cannot reopen to support other action potentials
29
succinylcholine uses
- IV rapid and short lasting block -Phase 1 block - used to facilitate intubation - used illegally in blow hunting or euthansia - in an emergency can be given IM, but slower and less predictable action
30
succinyl choline side effects
- bradycardia - hyperkalaemia - incr intra-ocular and intragastric pressure - anaphylaxis - malignant hyperthermia
31
succinylcholine sensitive species
dogs, cattle and sheep are sensitive, horse and pigs less so
32
depolarising blocking agents phases
- I | - II
33
phase I block
depolarising block of motor end plate | -block is augmented, not reversed by cholinesterase inhibitors
34
phase II block
after repolarisation the membrane cannot easily be depolarised again
35
depolarising agents onset
rapid, 1min
36
depolarising agents duration
short, however may revert to phase II block
37
depolarising agents termination of action
metabolised by the plasma, pseudocholinesterase and liver
38
depolarising agents initial metabolite
succinylmonocholine, weaker, predominantly competitive blocking action
39
depolarising agents effect on muscle
- fasculation - weakness - paralysis
40
depolarising agents effect on cardiovascular system
- incr blood pressure | - incr/decr heart rate - stim of parasympathetic and or sympathethic ganglia
41
depolarising agents can be enhanced or potentiated by which
neostigmine, organophosphates and isoflurane
42
depolarising agents undesirable side effects
- muscle fasciculation, hyperkalamia - phase II block - malignant hyperthermia in genetically susceptible animals - muscarinic actions at high doses
43
depolarising agents advantages
short duration of action, little histamine release
44
competitive non depolarising neuromuscular blocking agents mechanism of action
selectively antagonise nicotinic receptors, thus preventing endogenous Ach binding and subsequent muscle cell depolarisation
45
competitive neuromuscular blocking agents groups
- benzylisoquinoline - aminosteroid - gallamine
46
benzylisoquinoline group examples
- d tubocurarine - atracurium - cisatracurium - mivacurium
47
aminosteroid group examples
- pancuronium - vecuronium - rocuronium
48
benzylisoquinoline group metabolism
metabolism in blood plasma, histamine release
49
aminosteroid group metbaolism
metabolism in liver, no histamine release
50
classifications of agents based on their duration of action
- ultra short - short - intermediate - long duration
51
intermediate agents examples
- atracurium - cisatracurium - rocuronium - vecuronium
52
long duration agents examples
- d tubocurare - dimethyltubocurarine - pancuronium - gallamine
53
effects of competitive blockers on cardiovascular system
- decr blood pressure -due to histamine release - incr heart rate - baroreceptor reflex - coagulobility of blood decr - due to release of heparin from mast cells
54
d tubocurare features
- long acting - slow onset of action - slight hypotension and tachycardia - histamine release - excretion via urine - limited use
55
mivacurium features
- short acting - succinycholine alternative developed for human use - HA release, hypotension can occur - metabolism in plasma
56
atracurium features
- intermediate acting - safe in liver and kidney disease - bradycardia may occur during surgical manipulations - precipitates in alkaline pH - can cause HA release at higher doses - probably most used in veterinary medicine
57
cisatracurium features
- immediate acting - R-cis isomer of atracurium - 3-4x potency - immediate onset - metabolism in plasma - frequently used in opthmologic surgeries
58
rocuronium
- intermediate acting - rapid onset of action - metabolism in liver, excretion with bile - lack of CV or HA-releasing effects - quite frequently may cause anaphylactic reaction
59
vecuronium features
- intermediate acting - lack of CV or HA releasing effects - drug of choice when CV stability needed - metabolism in liver - excretion with bile and urine - mydraitic use in birds and reptiles
60
pancurium features
- slight tachycardia and hypertension - metabolism in liver, elimination via urine - liver and kidney disease prolongs its effect
61
gallamine features
- frequently used in human surgery - tachycardia and hypertension - no HA release - crosses placental barrier
62
antagonists of competitive blockers
cholinesterase inhibitors or tetanic stimulation
63
whats used to control the muscarinic side effect of neostigmine
atropine

Pharmacology (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions